TY - JOUR
T1 - Malignant Transformation in Pleomorphic Adenoma
T2 - The Impact of DNA Methylation Profiling and Pathogenic Mutations
AU - Uro-Coste, Emmanuelle
AU - Nicaise, Yvan
AU - Akiki, Béatrice
AU - Decamps, Clementine
AU - Chaltiel, Léonor
AU - Siegfried, Aurore
AU - Herbault-Barres, Beatrice
AU - Reboul, Hadrien
AU - Bassey, Emmanuella
AU - Modesto, Anouchka
AU - Poissonnet, Valentine
AU - Even, Caroline
AU - Verillaud, Benjamin
AU - Costes-Martineau, Valérie
AU - Ferrand, François Regis
AU - Vergez, Sebastien
AU - Cohen-Jonathan-Moyal, Elizabeth
N1 - Publisher Copyright:
© 2025 The Authors
PY - 2025/9/1
Y1 - 2025/9/1
N2 - Salivary gland tumors are a rare and heterogeneous group of lesions with diverse microscopic appearances and variable clinical behavior. The most common salivary gland tumor subtype, pleomorphic adenoma (PA), can undergo malignant transformation into carcinoma ex pleomorphic adenoma (CXPA). Carcinomatous transformation from PA to CXPA is a highly progressive and multistep process. Distinguishing a PA with some atypia from a low-grade intracapsular or minimally invasive CXPA is primarily subjective as no mitotic count thresholds exist to help pathologists distinguish between them in difficult cases. In this prospective study, we collected 140 cases encompassing both PA and CXPA to study their molecular signatures. The primary objective was to investigate the use of DNA methylation profiling as a potential molecular tool for differentiating between these 2 entities. Methylation analysis was performed on 33 PA cases and 33 CXPA cases. We were able to demonstrate that based on their methylation profiles, PA and CXPA could be classified into 3 distinct clusters that we called benign, intermediate, and malignant. We also revealed that the presence of TP53, HRAS, PTEN, and/or TERT pathogenic mutations were exclusively present in CXPA cases and that chromosomal alteration on chromosomes 5 and 8 are potentially associated with malignant transformation. In conclusion, our study provides a comprehensive molecular framework for PA and CXPA. The presence of a pathogenic mutation in TP53, HRAS, PTEN, or pTERT or HER2 amplification could be integrated into a molecular diagnosis of CXPA for tumors within the PA–CXPA spectrum. In the future, we aim to improve our methylomic classification to make it a precision medicine diagnostic tool for the treatment management of tumors within the PA–CXPA spectrum.
AB - Salivary gland tumors are a rare and heterogeneous group of lesions with diverse microscopic appearances and variable clinical behavior. The most common salivary gland tumor subtype, pleomorphic adenoma (PA), can undergo malignant transformation into carcinoma ex pleomorphic adenoma (CXPA). Carcinomatous transformation from PA to CXPA is a highly progressive and multistep process. Distinguishing a PA with some atypia from a low-grade intracapsular or minimally invasive CXPA is primarily subjective as no mitotic count thresholds exist to help pathologists distinguish between them in difficult cases. In this prospective study, we collected 140 cases encompassing both PA and CXPA to study their molecular signatures. The primary objective was to investigate the use of DNA methylation profiling as a potential molecular tool for differentiating between these 2 entities. Methylation analysis was performed on 33 PA cases and 33 CXPA cases. We were able to demonstrate that based on their methylation profiles, PA and CXPA could be classified into 3 distinct clusters that we called benign, intermediate, and malignant. We also revealed that the presence of TP53, HRAS, PTEN, and/or TERT pathogenic mutations were exclusively present in CXPA cases and that chromosomal alteration on chromosomes 5 and 8 are potentially associated with malignant transformation. In conclusion, our study provides a comprehensive molecular framework for PA and CXPA. The presence of a pathogenic mutation in TP53, HRAS, PTEN, or pTERT or HER2 amplification could be integrated into a molecular diagnosis of CXPA for tumors within the PA–CXPA spectrum. In the future, we aim to improve our methylomic classification to make it a precision medicine diagnostic tool for the treatment management of tumors within the PA–CXPA spectrum.
KW - DNA methylation profiles
KW - carcinoma ex pleomorphic adenoma
KW - pathogenic mutations
KW - pleomorphic adenoma
UR - http://www.scopus.com/inward/record.url?scp=105007134441&partnerID=8YFLogxK
U2 - 10.1016/j.modpat.2025.100786
DO - 10.1016/j.modpat.2025.100786
M3 - Article
C2 - 40311763
AN - SCOPUS:105007134441
SN - 0893-3952
VL - 38
JO - Modern Pathology
JF - Modern Pathology
IS - 9
M1 - 100786
ER -